In vivo -- rats and mice (topical and IP administration). In vitro -- rat vibrissa follicle clonogenic keratinocytes (stem-cell-like cells from the follicle bulge region). This is the landmark study by Philp et al., 2004, published in FASEB Journal -- a high-impact, peer-reviewed journal.

Tβ4 stimulated hair growth in normal rats and mice. A specific subset of keratinocytes in the hair follicle bulge (the stem cell niche) expressed Tβ4 in a coordinated manner during the hair cycle. In vitro, these bulge-derived keratinocytes showed increased migration and differentiation at nanomolar Tβ4 concentrations. Expression of MMP-2 (a matrix-remodeling enzyme essential for follicle extension during anagen) was increased. A 2007 follow-up confirmed these results across multiple rodent models, including a transgenic Tβ4-overexpressing mouse.

This is real, well-conducted science published in a top-tier journal. The mechanism is directly relevant to hair biology -- stem cell activation in the bulge region is exactly how follicles re-enter the growth phase. The data is stronger than anything in BPC-157's portfolio for hair. However, it's still animal data. Rat vibrissa follicles are not human scalp follicles. Mice have a synchronized hair cycle that humans don't. And no one has tested whether topical or injected Tβ4/TB-500 stimulates human hair follicle stem cells.

• Philp D et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J PMID 14657002
• Philp D et al. (2007). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Ann NY Acad Sci PMID 17947589

In vivo -- transgenic Tβ4-overexpressing mice AND Tβ4 global knockout mice (Gao et al., 2015-2016). This is powerful genetic evidence: if you overexpress the gene, the pathway goes up; if you knock it out, the pathway goes down.

In Tβ4-overexpressing mice, β-catenin and LEF-1 expression increased, along with MMP-2 and VEGF. In knockout mice, the opposite pattern was observed. The overexpressing mice had faster hair growth and altered follicle patterns; knockout mice had slower regrowth and fewer follicles. The proposed mechanism: Tβ4 regulates VEGF and MMP-2 via the Wnt/β-catenin/LEF-1 signaling pathway.

This is the strongest mechanistic evidence connecting any peptide in this guide to the Wnt/β-catenin pathway -- and Wnt signaling is arguably the most important pathway for hair follicle cycling. Unlike GHK-Cu's Wnt claim (which comes from computational analysis of cancer cell lines), this is actual genetic evidence in a relevant tissue. The use of both overexpression and knockout models provides bidirectional confirmation. Important translational caveat: these changes come from constitutive genetic models -- lifelong overexpression and global knockout -- in healthy mice with depilation-induced hair cycling, not from administering TB-500 to follicles in a diseased state. No pharmacological or topical TB-500 was tested, and Wnt activation that promotes growth in a healthy, fully cycling follicle does not necessarily translate to androgenetic alopecia, where follicles are miniaturizing under DHT-driven, Wnt-suppressive conditions. The limitation remains that it's mouse genetic data, and mouse hair biology doesn't perfectly translate to humans.

• Gao X et al. (2015). Thymosin Beta 4 Promotes Hair Growth in Transgenic Mice. PLOS ONE PMID 26083021
• Gao X et al. (2016). Thymosin Beta 4 Promotes Hair Growth via the Wnt/β-catenin Signaling Pathway. Mol Genet Genomics PMID 27130465

In vitro -- rat vibrissa keratinocytes (Philp 2004). In vivo -- transgenic/knockout mice (Gao 2016).

Tβ4 upregulates both expression and secretion of MMP-2, a matrix metalloproteinase that degrades denatured collagen, fibronectin, and other ECM components. This remodeling separates follicle structures from the basement membrane -- essential for follicle extension during anagen.

MMP-2-mediated ECM remodeling is a legitimate hair-relevant mechanism. The data comes from the same well-conducted Philp and Gao studies discussed above. As with the other hair claims, this has not been validated in human tissue.

• Philp D et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J PMID 14657002
• Gao X et al. (2016). Thymosin Beta 4 Promotes Hair Growth via the Wnt/β-catenin Signaling Pathway. Mol Genet Genomics PMID 27130465

In vivo -- multiple animal models (normal rats, diabetic mice, steroid-treated rats, aged mice). Also human Phase II clinical trials for pressure ulcers, stasis ulcers, and epidermolysis bullosa. The landmark animal study (Malinda et al., 1999) showed Tβ4 increased re-epithelialization by 42% at day 4 and up to 61% at day 7 versus controls, with increased collagen deposition and angiogenesis.

In Phase II human trials, topical Tβ4 accelerated wound healing by almost a month in patients who did heal. Keratinocyte migration was stimulated 2-3 fold at doses as low as 10 picograms in vitro.

This is one of the stronger evidence bases for any peptide: consistent animal data across multiple wound types, a clear mechanism (cell migration, stem cell mobilization, reduced inflammation), and Phase II human data showing real clinical benefit. The wound healing evidence is what originally drove the clinical development program.

• Malinda KM et al. (1999). Thymosin beta4 accelerates wound healing. J Invest Dermatol PMID 10469335
• Treadwell T et al. (2012). The regenerative activities of thymosin β4 in the healing of wounds. Ann NY Acad Sci PMID 23050815

Human clinical trials -- Phase II and Phase III. The ophthalmic program (RGN-259, 0.1% Tβ4 eye drops) is TB-500's most advanced clinical application.

Phase II dry eye trial (N=72, double-masked RCT): 27% reduction in ocular discomfort, significant improvement in corneal staining (p=0.0075 central, p=0.0210 superior). Phase II severe dry eye (N=9): 35.1% reduction in discomfort (p=0.0141), 59.1% reduction in corneal staining (p=0.0108). Phase III neurotrophic keratopathy (SEER-1, N=18): 60% achieved complete corneal healing at 4 weeks vs 12.5% placebo. However, a later Phase III trial (SEER-3) missed its primary endpoint.

This is the closest any peptide in this guide has come to formal clinical validation. The Phase II results are impressive, and SEER-1 showed meaningful healing in a difficult condition. The SEER-3 failure is an important caveat -- it shows that even promising Phase II results don't always replicate in larger trials. No drug is FDA-approved based on this data yet.

• Sosne G, Ousler GW (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol PMID 26056426
• Sosne G et al. (2015). Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases. Cornea PMID 25826322
• Sosne G et al. (2023). Thymosin Beta 4 for Neurotrophic Keratopathy: SEER-1 Phase III Results. Int J Mol Sci PMID 36614008

In vivo -- mouse coronary artery ligation (MI model). Published in Nature (Bock-Marquette et al., 2004) and Nature (Smart et al., 2007) -- two of the highest-impact publications for any peptide discussed in this guide. Also Phase II human clinical trial (NCT01311518, ~75 subjects).

Tβ4 promoted cardiomyocyte migration and survival through the PINCH/ILK/Akt pathway. After coronary ligation in mice, it enhanced early myocyte survival and improved cardiac function. A separate Nature paper showed Tβ4 mobilizes adult epicardial progenitor cells -- essentially reactivating dormant cardiac stem cells -- to form new blood vessels. The Phase II trial reportedly showed efficacy, though full results are available only via a RegeneRx press release.

Two Nature papers establish the cardiac mechanism with exceptional rigor. The epicardial progenitor mobilization finding is particularly striking -- it shows Tβ4 can restore pluripotency in adult cells. The clinical data (Phase II) reportedly showed benefit, but full peer-reviewed publication of the cardiac trial results hasn't been located.

• Bock-Marquette I et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature PMID 15565145
• Smart N et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature PMID 17108969
• RegeneRx Biopharmaceuticals (2013). Phase II Clinical Trial of RGN-352 for Acute Myocardial Infarction. ClinicalTrials.gov

Human Phase I -- randomized, placebo-controlled trial (Ruff et al., 2010). Four cohorts of 10 healthy subjects each received ascending IV doses: 42, 140, 420, or 1,260 mg. After safety review, the same dose was given daily for 14 days. A second Phase I trial in China (Wang et al., 2021) tested ascending doses in 84 healthy volunteers.

Adverse events were infrequent, mild or moderate. No dose-limiting toxicities. No serious adverse events at any dose up to 1,260 mg IV. Half-life ranged from 0.95h (42 mg) to 2.1h (1,260 mg). The Chinese trial confirmed the safety profile with no serious adverse events across all dose cohorts.

This is the strongest safety data for any peptide in this guide, by a wide margin. Two independent Phase I trials (US and China), proper randomization and controls, ascending doses up to gram-level IV administration with no safety signals. However, this applies to pharmaceutical-grade Tβ4 -- not necessarily to research-grade TB-500 from peptide vendors.

• Ruff D et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann NY Acad Sci PMID 20536472
• Wang D et al. (2021). Safety and pharmacokinetics of thymosin beta 4 in healthy Chinese subjects: A Phase I clinical trial. J Cell Mol Med PMID 34346165

In vivo -- mouse models of renal fibrosis (unilateral ureteral obstruction), pulmonary fibrosis (bleomycin-induced), hepatic fibrosis, and cardiac fibrosis. Key finding: the anti-fibrotic activity resides primarily in Ac-SDKP, the N-terminal cleavage product of Tβ4.

Ac-SDKP reduced collagen and fibronectin deposition, decreased myofibroblast numbers and macrophage infiltration, and suppressed profibrotic factors (TGF-β, CTGF, α-SMA) across kidney, lung, and liver models. In pulmonary fibrosis, it significantly decreased mortality, weight loss, and fibrosis markers when given both preventively and therapeutically.

The anti-fibrotic data is consistent across organs and mechanisms. The Ac-SDKP distinction is important for hair: perifollicular fibrosis is associated with advanced androgenetic alopecia, so an anti-fibrotic peptide could theoretically help maintain the follicular environment. This hasn't been tested in scalp tissue, but the biological logic is sound. The fact that the anti-fibrotic activity comes from a cleavage product (Ac-SDKP) rather than intact Tβ4 adds a layer of complexity about whether topical TB-500 would produce this effect.

• Kleinman HK et al. (2023). Thymosin beta 4 and its anti-fibrotic activities. Int Immunopharmacol PMID 36580759
• Zuo Y et al. (2013). Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int PMID 23739235
• Conte E et al. (2016). Thymosin beta 4 reduces IL-17A-producing cells and IL-17A expression, and protects lungs from damage in bleomycin-treated mice. Oncotarget PMID 27029074

In vivo -- rat models of traumatic brain injury (CCI model, Xiong et al., 2012) and embolic stroke (MCAo model, Morris et al., 2010). Both from the Chopp group at Henry Ford Hospital, a well-respected neurotrauma research center.

After TBI, Tβ4 treatment started 6 hours post-injury improved sensorimotor recovery, reduced cortical lesion volume, decreased hippocampal cell loss, and enhanced neurogenesis in the dentate gyrus. After embolic stroke, Tβ4 started 24 hours post-stroke improved neurological scores, increased myelinated axons, and augmented remyelination by mobilizing oligodendrocyte progenitor cells.

The neurotrauma data comes from an independent, respected lab (Henry Ford Hospital), which adds credibility. The delayed treatment windows (6h post-TBI, 24h post-stroke) are clinically relevant. No human trials for neurological indications have been reported.

• Xiong Y et al. (2012). Thymosin β4 treatment of traumatic brain injury in the rat. J Neurosurg PMID 22324420
• Morris DC et al. (2010). Thymosin beta 4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience PMID 20627173